Browsing publications by Dr Ross Maxwell

Newcastle AuthorsTitleYear
Emma Haagensen
Suzanne Kyle
Dr Gary Beale
Dr Ross Maxwell
Professor Herbie Newell
et al.		The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition2012
Dr Sanjoy Chatterjee
Dr John Wilsdon
Dr Judith Mott
Paddy Stevenson
Dr Ross Maxwell
et al.		Final Results of Vortigern Study: CT Versus Pet-CT Based Tomotherapy Voluming and Dose Escalation in Oropharyngeal Squamous Cell Carcinoma (ISRCTN 33175361, UKCRN ID: 08/h0907/127) [meeting abstract]2011
Henrike Knizia
Michael Batey
Gilberto de Almeida
Dr Ross Maxwell
Dr Petra Dildey
et al.		Development of an orthotopic model for human malignant bone diseases in immunocompromised NOD.Cg-PrkdcscidIl2rgtmlwjl/szj (NSG) mice2010
Dr Ross Maxwell
Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates2010
Dr Ross Maxwell
John Wilson
Carbogen breathing increases prostate cancer oxygenation: A translational MRI study in murine xenografts and humans2009
Dr Ross Maxwell
[Meeting Abstract] Combretastatin activity in tumours: factors of importance2008
Dr Ross Maxwell
Preclinical Studies to Predict Efficacy of Vascular Changes Induced by Combretastatin A-4 Disodium Phosphate in Patients2008
Dr Ross Maxwell
Segmentation of dynamic contrast enhanced magnetic resonance imaging data2008
Dr Ross Maxwell
Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.2006
Dr Ross Maxwell
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: acomparative assessment using MRI and MRS2006
12